Skip to product information
1 of 1

GeneBio Systems

Recombinant Human BLK Protein (GST Tag)

Recombinant Human BLK Protein (GST Tag)

SKU:PKSH030381

Regular price $879.00 USD
Regular price Sale price $879.00 USD
Sale Sold out
Shipping calculated at checkout.

Size: 50μg

Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: B Lymphocyte Kinase;BLK;MODY11;Tyrosine-Protein Kinase Blk;p55-Blk

Research Areas: Cell biology

Conjugation:

Target Species: Human

Expression Host: Baculovirus-Insect Cells

Application: Enzyme

Fusion tag: N-GST

UNIProt ID: P51451

Accession: NP_001706.2

Background: Tyrosine-protein kinase Blk, also known as B lymphocyte kinase, p55-Blk and BLK, is a member of theprotein kinase superfamily, Tyr protein kinase family and SRC subfamily. BLK / p55-Blk is expressed in lymphatic organs, pancreatic islets, Leydig cells, striate ducts of salivary glands and hair follicles. BLK / p55-Blk is a src-family protein tyrosine kinase specifically expressed in B-lineage cells of mice. The early onset of Blk expression during B-cell development in the bone marrow and the high expression levels of Blk in mature B cells suggest a possible important role of Blk in B-cell physiology. It is a modulator of beta-cells function, acting through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose. Defects in BLK are a cause of maturity-onset diabetes of the young type 11 which is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

Concentration:

Activity: The specific activity was determined to be 17.4 nmol/min/mg using Poly(Glu, Tyr)4:1 peptide as substrate.

Sequence: Met 1-Pro 505

Purity: > 88 % as determined by reducing SDS-PAGE.

Formulation: Supplied as sterile solution of 20mM Tris, 500mM NaCl, 5mM GSH, pH 7.4

Reconstitution: Not Applicable

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 84 kDa

ObservedMW: 84 kDa

View full details